Positive Assessment Issued for Agendiaโs MammaPrintยฎ
PRESS RELEASE Determination finds that Agendiaโs MammaPrintยฎ Breast Cancer Risk Read More
New Studies Show MammaPrintยฎ and BluePrintยฎ Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment
PRESS RELEASE New Studies Show MammaPrintยฎ and BluePrintยฎ Tests Provide Read More
New Research to be Presented at SABCS 2018 Reinforces MammaPrint and BluePrint Testing to Guide Breast Cancer Treatment Management Decisions
PRESS RELEASE Agendia Announces New Research Reinforcing MammaPrintยฎ and BluePrintยฎ Read More
Oncology Consultants Joins Agendiaโs FLEX Big Data Registry Study
PRESS RELEASE Oncology Consultants Join Agendiaโs FLEX Big DataRegistry Study, Read More
Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrintยฎ and BluePrintยฎ to Predict Treatment Response in Breast Cancer Patients
ย PRESS RELEASE Latest Results from the I-SPY 2 Trial at Read More
Agendia Announces Level 1 Inclusion of MammaPrintยฎ Breast Cancer Test in Updated National Comprehensive Cancer Networkยฎ (NCCN) Guidelines
PRESS RELEASE Agendia Announces Level 1 Inclusion of MammaPrintยฎ Breast Read More
Agendia and Genecast Biotechnology Partner to Launch MammaPrint and BluePrint in China
For the first time, early-stage breast cancer patients and their Read More
US Oncology Research Joins Agendiaโs FLEX Big Data Initiative, Accelerating Diagnostic Discoveries in Breast Cancer and Enabling Precision Oncology
Dataset of up to 10,000 full genome profiles matched with Read More
An Update on Agendiaโs Precision Oncology Achievements in Breast Cancer
As we close out the first half of 2018, Iโd Read More
Agendia Secures $35 Million Investment from Funds Managed by Athyrium Capital Management to Support Expanded Commercial Footprint in Rapidly Growing Markets and New Research Collaborations
IRVINE, CA and AMSTERDAM, NETHERLANDS โ 25 July 2018 โ Read More
